Eli Lilly and Company $LLY Shares Acquired by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 7.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,713 shares of the company’s stock after purchasing an additional 3,829 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Edmond DE Rothschild Holding S.A.’s investment portfolio, making the stock its 29th largest holding. Edmond DE Rothschild Holding S.A.’s holdings in Eli Lilly and Company were worth $65,621,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. GW&K Investment Management LLC increased its stake in shares of Eli Lilly and Company by 2.9% in the 3rd quarter. GW&K Investment Management LLC now owns 21,476 shares of the company’s stock worth $24,849,000 after acquiring an additional 610 shares in the last quarter. Private Wealth Asset Management LLC raised its position in shares of Eli Lilly and Company by 89.1% during the third quarter. Private Wealth Asset Management LLC now owns 21,212 shares of the company’s stock valued at $24,544,000 after buying an additional 9,997 shares during the last quarter. Greenline Wealth Management LLC raised its position in shares of Eli Lilly and Company by 1.6% during the third quarter. Greenline Wealth Management LLC now owns 622 shares of the company’s stock valued at $720,000 after buying an additional 10 shares during the last quarter. Hill Investment Group Partners LLC grew its stake in Eli Lilly and Company by 2.7% during the third quarter. Hill Investment Group Partners LLC now owns 379 shares of the company’s stock valued at $439,000 after acquiring an additional 10 shares in the last quarter. Finally, Private Advisor Group LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at approximately $114,827,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. Barclays raised their price target on shares of Eli Lilly and Company from $1,400.00 to $1,550.00 and gave the company an “overweight” rating in a research note on Monday. Royal Bank Of Canada restated an “outperform” rating and set a $1,600.00 price target on shares of Eli Lilly and Company in a research report on Tuesday. Leerink Partners boosted their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,422.00.

Check Out Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Price Performance

LLY opened at $1,352.18 on Friday. The stock’s 50-day moving average price is $1,263.45 and its 200 day moving average price is $1,117.53. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The firm has a market cap of $1.27 trillion, a price-to-earnings ratio of 43.89, a PEG ratio of 1.65 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period last year, the business posted $7.02 EPS. The company’s revenue was up 38.6% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

More Eli Lilly and Company News

These are some of the LLY news items that stood out recently:

  • Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce major cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, expanding the medicine’s potential use. Health Canada approves Lilly’s Mounjaro to reduce cardiovascular risk
  • Neutral Sentiment: Lilly’s 2026 acquisition spending has surpassed $32 billion, including deals aimed at building cancer and immunology capabilities. The investments could strengthen future growth but also raise execution and capital-allocation questions. Lilly buying spree surpasses $32 billion
  • Negative Sentiment: Valuation remains a key concern: commentary described Lilly’s roughly $1.4 trillion valuation as dependent on substantial future growth, while another analysis questioned whether shares near record highs still offer attractive upside. This may make the stock vulnerable to profit-taking or any disappointment. Eli Lilly’s $1.4 trillion valuation is heavy with hope

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.